Formulated specifically for individual medical device applications, Serene Single-Coat (SC) solutions will enable manufacturers to use their legacy coating process to apply this surface treatment.
Serene hydrophilic coatings, which can bond to different substrates, can be used for peripheral, neurovascular and structural heart devices.
The coatings will be applied by using firm’s patented Photolink UV curing process, which covalently bonds surface treatments to substrates at ambient temperature.
The technology can be easily integrated into existing manufacturing processes, in addition to reducing production time and reagent costs compared to both thermal-curing and alternative light-activated processes.
Hydrophilic coatings are said to reduce risk of damage to blood vessel walls, as well as enable physicians to reach distal treatment sites for procedures for improved therapeutic outcomes.
Surmodics president and CEO Gary Maharaj said: “With regulatory attention increasingly focused on lowering particulates, we’ve experienced quick adoption of Serene coatings among manufacturers already equipped for a two-coat process.
“Serene SC solutions will broaden the range of medical device companies able to benefit from the unmatched lubricity and durability this product family provides.”
Surmodics offers surface modification technologies for intravascular medical devices, as well as chemical components for in vitro diagnostic (IVD) tests and microarrays.
The company acquired Creagh Medical and NorMedix to expand its intravascular product solutions for medical device customers.
